{"classes":[{"categories":[{"measurements":[{"comment":"Values were non-estimable (insufficient number of participants with events).","groupId":"OG000","lowerLimit":"38.7","upperLimit":"NA","value":"51.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"83"}],"units":"Participants"}],"description":"PFS was defined as time from first dose to the time of initial documentation of confirmed PD or death due to any cause, whichever occurred first. Participants who had not progressed or died at the time of analysis were censored at the last response assessment that was SD or better.","dispersionType":"95% Confidence Interval","groups":[{"description":"Avapritinib was administered once daily as an immediate-release tablet, orally, in 28-day cycles.","id":"OG000","title":"Avapritinib"}],"paramType":"MEDIAN","populationDescription":"Response-evaluable Population: all participants who received ≥1 dose of avapritinib, were deemed evaluable per mIWG-MRT-ECNM criteria at baseline as assessed by study steering committee review and had 1 of the following conditions: ≥2 complete postbaseline bone marrow assessments, and had been on study for ≥6 cycles; had an end of study visit.","reportingStatus":"POSTED","timeFrame":"Baseline through Month 65","title":"Progression-free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"Months"}